Mortimer Ian's Form 4 filing
Xenon Pharmaceuticals Inc.XENE · filed May 26, 2023
- Accession no.
- 0000950170-23-024600
- Filed
- May 26, 2023
- Trade date
- May 24, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 9 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.31M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mortimer IanCIK 0001619961 | Director, Officer (PRESIDENT & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 24, 2023 | Common Shares | MOption exerciseAcquired | +42,592 | $9.44F1 | +$402,068.48 | 48,592 | Direct | |
| May 24, 2023 | Common Shares | FTax withholdingDisposed | −7,310 | $41.84F2 | −$305,850.4 | 41,282 | Direct | |
| May 24, 2023 | Common Shares | SSaleDisposed | −17,069 | $41.44F3 | −$707,339.36 | 24,213 | Direct | |
| May 24, 2023 | Common Shares | MOption exerciseAcquired | +20,576 | $9.85F4 | +$202,673.6 | 44,789 | Direct | |
| May 24, 2023 | Common Shares | FTax withholdingDisposed | −3,902 | $41.84F2 | −$163,259.68 | 40,887 | Direct | |
| May 24, 2023 | Common Shares | SSaleDisposed | −13,179 | $41.37F5 | −$545,215.23 | 27,708 | Direct | |
| May 24, 2023 | Common Shares | MOption exerciseAcquired | +6,172 | $9.85F4 | +$60,794.2 | 33,880 | Direct | |
| May 24, 2023 | Common Shares | FTax withholdingDisposed | −1,171 | $41.84F2 | −$48,994.64 | 32,709 | Direct | |
| May 24, 2023 | Common Shares | SSaleDisposed | −1,407 | $41.49F6 | −$58,376.43 | 31,302 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 24, 2023 | Common Shares | MOption exerciseDisposed | −42,592 | $0.00 | $0 | 0 | Direct | |
| May 24, 2023 | Common Shares | MOption exerciseDisposed | −20,576 | $0.00 | $0 | 0 | Direct | |
| May 24, 2023 | Common Shares | MOption exerciseDisposed | −6,172 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The exercise price was converted from $9.76 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
Referenced by the price of 1 transaction in Table I.
- F2
Represents the closing price of the Company's common shares on May 23, 2023 for purposes of net settlement calculations.
Referenced by the price of 3 transactions in Table I.
- F3
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.29 to $41.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
- F4
The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock Split. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
Referenced by the price of 2 transactions in Table I.
- F5
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.26 to $41.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.
- F6
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.48 to $41.52, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Referenced by the price of 1 transaction in Table I.